Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Cardioprotection, and Neurobiology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ERBB4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERBB4 ECD-Fc Fusion Protein / Mutant Protein (Met1-Pro651, HEK293 expressed, native glycosylation, >95% purity, <1 EU/ug endotoxin, sequence verified) | View ERBB4 Products |
| Isoform Panel | ERBB4 JM-a vs JM-b variant recombinant proteins (ECD+transmembrane) to distinguish cleavable and non-cleavable isoforms for shedding assays | View ERBB4 Products |
| Ligand (NRG1) | NRG1-beta1 Protein (HEK293-derived, high purity, endotoxin controlled). Primary endogenous ligand driving ERBB4 activation | View NRG1 Products |
| Gene Delivery | ERBB4 Promise-ORF / Lentivirus (full-length wild-type and clinically relevant mutants such as E317K, E872K for stable cell line construction; nuclear translocation compatible) | View ERBB4 Products |
| Benchmark Ab | Anti-ERBB4 Reference Antibody (recombinant positive control for Western blot, flow cytometry, and assay calibration) | View ERBB4 Products |
| Validator | ERBB4 siRNA Set (for specific knockdown verification and specificity controls) | View ERBB4 Products |
| Dimerization Partner | ERBB2 (HER2) ECD-Fc (required for functional ERBB4 heterodimerization and cardiac safety profiling) | View ERBB2 Products |
| Related Target A | NRG1 (Neuregulin-1; primary ligand, drives ERBB4 dimerization and downstream signaling) | View NRG1 Products |
| Related Target B | ERBB2 (HER2; preferred oncogenic dimerization partner; essential for signaling and cardiac safety) | View ERBB2 Products |
| Related Target C | EGFR (HER1; essential pan-HER family homolog for selectivity counter-screening and toxicity assessment) | View EGFR Products |
| Related Target D | ERBB3 (HER3; compensatory pathway member; co-expression determines NRG1 sensitivity and resistance mechanisms) | View ERBB3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pan-HER Family Counter-Screening & Selectivity | Human homolog panel (EGFR, ERBB2, ERBB3, ERBB4) >95% purity verified by SDS-PAGE and mass spectrometry |
| Kinase Domain Somatic Mutation Evaluation | Sequence-verified mutant recombinant proteins (e.g., E317K, E872K) for structural and potency profiling of novel TKIs |
| Receptor Internalization for ADC Development | HEK293-expressed ECD-Fc fusion proteins with native human glycosylation ensuring physiologically relevant binding kinetics |
| Isoform-Specific Targeting (JM-a vs JM-b) | JM-a and JM-b variant proteins with verified intracellular domain sequences; distinguish sheddable vs non-sheddable populations |
| Nuclear Translocation Detection | Full-length ERBB4 Lentivirus with C-terminal tags compatible with confocal microscopy; preserves native cleavage sites |
| Heterodimerization Requirements | ERBB2/ERBB3 co-immunoprecipitation standards; verified protein-protein interaction controls; also support ERBB4-ERBB2 primary dimer disruption assays |
| NRG1-Driven Resistance Mechanisms | High-purity NRG1 ligand for ligand-competition assays; defined biological activity units |
| Cross-species Toxicology (Cardiac Safety) | Human/Mouse/Cynomolgus ERBB4 ortholog proteins (>85% sequence homology) for epitope conservation testing |
| False Positives in Signal Transduction/Binding Assays | Endotoxin-controlled (<1 EU/ug) reagents combined with validated siRNA panels and negative control proteins to establish absolute baseline specificity |
Live ERBB4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ERBB4 therapeutics is intensifying as researchers navigate its complex biology across oncology, cardiology, and neurology. While early-generation pan-HER tyrosine kinase inhibitors (TKIs) broadly suppressed EGFR, ERBB2, and ERBB4 simultaneously—often leading to dose-limiting EGFR-driven toxicities—the modern development paradigm emphasizes precision selectivity. Today, major players are shifting focus toward ERBB4-selective modulation (including isoform-selective monoclonal antibodies), targeted protein degraders (TPDs) leveraging the unique nuclear signaling capability of ERBB4 (via ICD cleavage), and allosteric inhibitors for neurological indications such as schizophrenia and ALS. The NRG1-ERBB4 signaling axis is gaining momentum for tissue repair, cardioprotection in heart failure, and neuroprotection. Furthermore, first-generation antibodies are navigating Phase I oncology trials, while bispecific ERBB4 x ERBB2 antibodies aim to disrupt compensatory heterodimerization in HER2-resistant tumors. TarMart supports all these modalities with a comprehensive, specification-first reagent ecosystem.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-HER & Selective TKIs | Puma Biotechnology, Boehringer Ingelheim, AstraZeneca | HER2-mutant NSCLC, Breast Cancer, Melanoma | Selectivity & Mutation Profiling (Homolog Panel & Mutant TK Proteins) |
| Isoform-Selective mAb | Academic Consortia, Biotech | Solid Tumors (NRG1-fusion driven) | JM-a vs JM-b binding selectivity (Isoform-specific ECD proteins) |
| Antibody-Drug Conjugates (ADCs) | Emerging Biotech, Academic Consortia, Pediatric Oncology Programs | Refractory Solid Tumors, Colorectal Cancer, Medulloblastoma | Internalization Kinetics (High-purity HEK293 ECD-Fc) |
| Recombinant Agonists / NRG1-based Therapies | Zensun (Neucardin), Acorda Therapeutics | Chronic Heart Failure, ALS, Neuroprotection | Receptor Dimerization Assay (High-purity NRG1 & ERBB4 ECD) |
| Bispecific / Multispecific Antibodies | Merck, Daiichi Sankyo, Oncology Biotechs | Metastatic Breast Cancer, Pan-HER Expressing Tumors | Heterodimer Disruption Assays (ERBB4/ERBB2 Complexes) |
| Targeted Protein Degrader (TPD) | Pharma (Undisclosed) | Resistance Mutations | Intracellular Domain Stability Assays (Full-length Lentivirus systems) |
| Allosteric Inhibitor | Neuroscience Focused Biotech | Schizophrenia, ALS | Conformational State Binding (Native-folded membrane preparations) |
Molecular Differentiation Strategy & Assay Development
To achieve best-in-class status for ERBB4-directed therapeutics, precise characterization of selectivity, isoform specificity, dimerization preference, and internalization efficiency is essential. Key assays include:
- Selectivity Panel: SPR/BLI-based cross-screening against EGFR, ERBB2, ERBB3, and ERBB4 to quantify KD ratios and minimize off-target toxicities.
- Mutant Kinase Inhibition: ADP-Glo or microfluidic enzymatic assays using recombinant ERBB4-WT and clinically relevant mutants (E317K, E872K, and the ALS-associated variant rs397514262) to assess resistance coverage.
- Internalization Kinetics: pH-sensitive fluorescent probe (pHrodo) assays on stable cell lines expressing full-length ERBB4 for ADC developability.
- Heterodimer Disruption: HTRF or AlphaLISA competition assays using purified ERBB4, NRG1, and ERBB2 proteins to quantify blockade of NRG1-induced ERBB4-ERBB2 dimerization.
- Isoform Mapping: SPR binding analysis on JM-a and JM-b isoforms to select antibodies that discriminate cleavable vs non-cleavable forms.
TarMart provides all necessary reagents: HEK293-expressed ECD-Fc with native glycosylation, full-length lentivirus for stable cell lines, mutant proteins, and ortholog panels for cross-species cardiac safety evaluation.
Related Target Cross-Selling Recommendations
- NRG1: Primary ligand for ERBB4; essential for all functional activation/dimerization assays.
- ERBB2 (HER2): Mandatory heterodimerization partner; required for cardiac safety profiling and combination therapy studies.
- EGFR (HER1): Key selectivity counter-screen to avoid EGFR-mediated toxicities.
- ERBB3 (HER3): Compensatory pathway; co-expression determines NRG1 sensitivity.
- ADAM17 / TACE: Protease responsible for shedding of JM-a isoform; tool compound for internalization studies.
Combine these with ERBB4 reagents for a complete NRG1-ERBB4-ERBB2 signaling axis solution.